Stereotactic body radiation therapy is increasingly used in the treatment of early-stage lung cancers. Guidelines provide indications regarding the constraints to the organs at risk (OARs) and the minimum coverage of the planning target volume but do not suggest optimal dose distribution. Data on dose distribution from the different published series are not comparable due to different prescription modalities and reported dose parameters.
Methods:
We conducted a review of the published data on dose prescription, focusing on the role of homogeneity on local tumor control, and present suggestions on how to specify and report the prescriptions to permit comparisons between studies or between cases from different centers.
Conclusions:
To identify the dose-prescription modality that better correlates with oncologic outcomes, future studies should guarantee a close uniformity of dose distribution between cases and complete dose parameters reporting for treatment volumes and OARs.
VansteenkisteJDe RuysscherDEberhardtWEE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2013; 24: vi89–vi98.
3.
BezjakAPaulusRGasparLE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non–small-cell lung cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol2019; 37: 1316–1325.
4.
RoachMCRobinsonCGDeWeesTA, et al. Stereotactic body radiation therapy for central early-stage NSCLC: results of a prospective phase I/II trial. J Thorac Oncol2018; 13: 1727–1732.
5.
ChangJYSenanSPaulMA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol2015; 16: 630–637.
6.
PalmaDASenanS. Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy. Clin Lung Cancer2013; 14: 1–5.
7.
OnishiHArakiTShiratoH, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer2004; 101: 1623–1631.
8.
GuckenbergerMAllgäuerMAppoldS, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol2013; 8: 1050–1058.
9.
ICRU Report 91. J ICRU2014; 14: 1–160.
10.
WilkeLAndratschkeNBlanckO, et al. ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol2019; 195: 193–198.
11.
GuckenbergerMWulfJMuellerG, et al. Dose–response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol2009; 74: 47–54.
12.
ZhangJYangFLiB, et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for stage I non–small-cell lung cancer? A meta-analysis. Int J Radiat Oncol2011; 81: e305–e316.
13.
WulfJBaierKMuellerG, et al. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol2005; 77: 83–87.
14.
OnimaruRFujinoMYamazakiK, et al. Steep dose–response relationship for stage 1 non–small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol2008; 70: 374–381.
15.
KestinLGrillsIGuckenbergerM, et al. Dose–response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance. Radiother Oncol2014; 110: 499–504.
16.
NagataYHiraokaMShibataT, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol2015; 93: 989–996.
17.
NymanJHallqvistALundJ-Å, et al. SPACE: a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol2016; 121: 1–8.
18.
FritzPKrausH-JBlaschkeT, et al. Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. Lung Cancer2008; 60: 193–199.
19.
MiyakawaAShibamotoYKosakiKHashizumeC. Early response and local control of stage I non-small-cell lung cancer after stereotactic radiotherapy: difference by histology. Cancer Sci2013; 104: 130–134.
20.
SakanakaKMatsuoYNagataY, et al. Safety and effectiveness of stereotactic body radiotherapy for a clinically diagnosed primary stage I lung cancer without pathological confirmation. Int J Clin Oncol2014; 19: 814–821.
21.
TimmermanRGalvinJMichalskiJ, et al. Accreditation and quality assurance for Radiation Therapy Oncology Group: multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol2006; 45: 779–786.
22.
BenedictSHYeniceKMFollowillD, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101: stereotactic body radiation therapy: the report of TG101. Med Phys2010; 37: 4078–4101.
23.
LuciaFKeySDissauxG, et al. Inhomogeneous tumor dose distribution provides better local control than homogeneous distribution in stereotactic radiotherapy for brain metastases. Radiother Oncol2019; 130: 132–138.
24.
van BaardwijkAToméWAvan ElmptW, et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol2012; 105: 145–149.
25.
GiglioliFRClementeSEspositoM, et al. Frontiers in planning optimization for lung SBRT. Phys Med2017; 44: 163–170.
26.
SongCWGlatsteinEMarksLB, et al. Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): indirect cell death. Int J Radiat Oncol 110: 21–34.
27.
GuckenbergerMKlementRJAllgäuerM, et al. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol2013; 109: 13–20.
28.
ShuryakICarlsonDJBrownJMBrennerDJ. High-dose and fractionation effects in stereotactic radiation therapy: analysis of tumor control data from 2965 patients. Radiother Oncol2015; 115: 327–334.
29.
GuckenbergerMKlementRJAllgäuerM, et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol2016; 118: 485–491.
30.
GiglioliFRStrigariLRagonaR, et al. Lung stereotactic ablative body radiotherapy: a large scale multi-institutional planning comparison for interpreting results of multi-institutional studies. Phys Med2016; 32: 600–606.
31.
ZhaoLZhouSBalterP, et al. Planning target volume D95 and mean dose should be considered for optimal local control for stereotactic ablative radiation therapy. Int J Radiat Oncol2016; 95: 1226–1235.
32.
MoustakisCBlanckOEbrahimi TazehmahallehF, et al. Planning benchmark study for SBRT of early stage NSCLC: results of the DEGRO Working Group Stereotactic Radiotherapy. Strahlenther Onkol2017; 193: 780–790.
33.
BaumannRChanMKHPyschnyF, et al. Clinical results of mean GTV dose optimized robotic-guided stereotactic body radiation therapy for lung tumors. Front Oncol2018; 8: 171.
34.
KatohNSodaITamamuraH, et al. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. Radiat Oncol2017; 12: 3.
35.
ZhengDZhangQLiangX, et al. Effect of the normalized prescription isodose line on the magnitude of Monte Carlo vs. pencil beam target dose differences for lung stereotactic body radiotherapy. J Appl Clin Med Phys2016; 17: 48–58.
36.
de JongEECGuckenbergerMAndratschkeN, et al. Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. Radiother Oncol2019; 142: 217–223.
37.
LacornerieTLisbonaAMirabelX, et al. GTV-based prescription in SBRT for lung lesions using advanced dose calculation algorithms. Radiat Oncol2014; 9: 233.
38.
GuckenbergerMAndratschkeNDieckmannK, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol2017; 124: 11–17.
39.
Tanadini-LangSWilkeLKaravaK, et al. EP-2197: dose normalization in lung SBRT based on ICRU 91 and comparison to alterative normalization methods. Radiother Oncol2018; 127: S1213–S1214.
40.
LoganadaneGMartinettiFMercierO, et al. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a critical literature review of predictive factors of relapse. Cancer Treat Rev2016; 50: 240–246.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
